State of the art in chemoradiotherapy combinations and potential role in targeting therapy approaches in nonsmall cell lung cancer

The preclinical rationale for chemoradiation was demonstrated. While chemoradiation allowed for improved outcome in nonsmall cell lung cancer patients, prognosis of patients remain particularly pejorative, encouraging major expansion of targeted therapies concurrently with radiotherapy. Thorough knowledge in biological mechanisms of oncogenesis permitted identifying new therapeutic targets, for which specific interactions allow pharmacological radiosensitivity modulation. Two modalities of EGFR inhibitors have been developed; monoclonal antibodies and tyrosin kinase inhibitors, which assessment remains are its begining. Angiogenesis inhibitions was also developed, illustrating the abolute necessity for careful clinical assessment. Drug with multiple targets are becoming available and offer new optimization modalities for radiation therapy.